Search

Displaying results 3731 - 3740 of 10000 in total
  1. Drug

    Larazotide

    go.drugbank.com/drugs/DB05645
    Investigational

    An octapeptide inhibitor of paracellular permeability whose structure is derived from a protein (zonula occludens toxin) secreted by Vibrio cholerae for treatment of Coeliac disease.

  2. Drug

    NNZ-2591

    go.drugbank.com/drugs/DB15601
    Investigational

    It was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019. … [L11100] Clinical trials are expected to begin in 2020.[L11103,L11100]

  3. Drug

    105AD7

    go.drugbank.com/drugs/DB05113
    Investigational

    105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in

  4. Drug

    99mTc-14 F7 Mab

    go.drugbank.com/drugs/DB05867
    Experimental

    99mTc 14F7 Mab has strong anti tumor activity against myeloma cells in vivo.

  5. Drug

    Bepotastine

    go.drugbank.com/drugs/DB04890
    Approved

    Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the … It is available in oral and opthalmic dosage forms in Japan. The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve.

  6. Drug

    TA-CIN

    go.drugbank.com/drugs/DB05809
    Investigational

    TA-CIN is a subunit vaccine comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16), designed to generate a strong cellular immune response against HPV-infected cells.

  7. Drug

    Cisapride

    go.drugbank.com/drugs/DB00604
    ApprovedWithdrawn

    In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias.

  8. Drug

    AX200

    go.drugbank.com/drugs/DB05093
    Investigational

    The expression of the endogenous AX200 protein in the brain is increased after brain damage. … Thus, if this drug administered in the acute phase of stroke, the brain’s own protective action is supported.

  9. Drug

    Interferon alfa-2a

    go.drugbank.com/drugs/DB00034
    ApprovedInvestigationalWithdrawn

    It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences. … A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes.

  10. Drug

    VLTS-589

    go.drugbank.com/drugs/DB05430
    Investigational

    VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.